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Recruiting Akt to the membrane-bound phosphatidylinositol (3,4,5) trisphosphate (PIP3) is required for Akt activation. While PI3 kinase
(PI3K) produces PIP3, PTEN dephosphorylates the 3-position phosphate from PIP3, thereby directly inhibiting Akt activation. PTEN is the
dominant PIP3 phosphatase, as knockdown of PTEN results in increases in Akt activation in mice. The PTEN tumor suppressor gene is frequently
mutated in a variety of human cancers, consistent with an inverse correlation between levels of the PTEN protein and Akt activation. We have
examined PTEN expression and Akt activation in 35 primary clear cell renal cell carcinomas RCCs (ccRCCs) and 9 papillary RCCs (pRCCs) and
their respective non-tumor kidney tissues. The PTEN protein was reduced in 16 ccRCCs (16/35=45.7%) and 8 pRCCs (8/9=88.9%). In these
RCCs, 25.0% (4/16) of ccRCCs and 25.0% (2/8) of pRCCs expressed elevated Akt activation. 19 ccRCCc (19/35=54.3%) expressed comparable
or higher levels of PTEN. Of these ccRCCs, 31.6% (6/19) showed increases in Akt activation. As PTEN dominantly inhibits Akt activation, the
coexistence of high levels of the PTEN protein with enhanced Akt activation suggests the existence of novel mechanisms which attenuate PTEN
function in ccRCC. These mechanisms may reduce PTEN function or increase PIP3 production.
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Kidney cancer accounts for nearly 3% of human malig-
nancies, affects 32,000 individuals, and causes 12,000 cancer
related deaths annually in the United States [1]. The disease
comprises a heterogeneous group of tumors, including primary
neoplasm of the renal pelvis or ureter (7–8%), Wilms tumor
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doi:10.1016/j.bbadis.2007.07.001of clear cell RCC (ccRCC) (80%), papillary RCC (pRCC)
(15%), and others with different histological features and factors
contributing to the behavior of the individual RCC [2].
A key pathway in the regulation of tumorigenesis, including
the formation of RCC, is the PI3K-Akt signaling pathway [3].
Growth factor signals such as VEGF, EGF, TGFα, and c-Met
whose functions are well known to promote RCC tumorigenesis
activate PI3K and Akt kinase [4]. Akt kinase activity then
reduces the activities of von Hippel Lindau (VHL) tumor
suppressor by stabilization of hypoxia inducible factor 1 (HIF-
1) [5,6] and TSC1/2 (tuberous sclerosis complex 1 and 2) tumor
suppressors, thereby activating mTOR (mammalian target of
rapamycin) kinase [7]. Inactivation of VHL and TSC1/2 and
activation of mTOR play critical roles in promoting RCC
tumorigenesis [4,8].
The major negative regulator of the PI3K-Akt pathway is
the dual protein/lipid phosphatase PTEN (phosphatase and
1135L. He et al. / Biochimica et Biophysica Acta 1772 (2007) 1134–1142tensin homologue deleted on chromosome 10). PTEN
antagonizes PI3K function [9], thereby preventing Akt
activation. This leads to induction of apoptosis and cell cycle
arrest in the G1 phase by increasing p27kip1 expression and
decreasing cyclin D1 expression [10,11]. Consistent with its
anti-proliferation functions, the PTEN gene is frequently muta-
ted in a variety of human cancers with concomitant increases
in Akt activation [9,10]. Germline mutations in PTEN contri-
bute to Cowden syndrome and Bannayan–Riley–Ruvalcaba
syndrome. Patients with these syndromes are at an increased
risk of breast, thyroid, and endometrial cancers [10] due to
activation of the PI3K-Akt pathway. This is consistent with
the observations that the PI3KCA gene, which encodes the
p110α catalytic subunit of the class IA PI3Ks, is one of the
two most mutated oncogenes in human cancer [12] and that
mutations in PIK3CA and in PTEN are mutually exclusive in
breast cancer [13]. Furthermore, PTEN+/− mice produce
tumors with elevated Akt activation [14], which is essentially
prevented if Akt1 is concomitantly knocked out [15]. Taken
together, accumulating evidence has shown that PTEN is a
predominant PI3K-Akt-negative regulator.
PTEN inactivation might also contribute to RCC pathology.
While loss of heterozygosity in the PTEN locus at 10q23.3
was detected in chromophobe RCC (chRCC) [16,17], muta-
tions in the remaining PTEN allele were not observed. This
reveals that loss of both PTEN alleles does not take place in
chRCC [16], suggesting that PTEN haploinsufficiency plays a
role in chRCC tumorigenesis. Consistent with this notion,
reduction of PTEN protein, via examination by immunohis-
tochemistry and western blot, was found in 12.5%–55% of
ccRCCs [17,18]. Furthermore, loss of PTEN function is
associated with advanced ccRCC and poor prognosis [19]. The
mortality rate for patients with PTEN-negative ccRCC was
approximately 90% compared to 45% for patients with PTEN-
positive ccRCC [19].
To address whether PTEN function can be attenuated in
RCC via mechanisms other than those which lead to a
decrease in PTEN protein, we have determined PTEN
function in ccRCC and pRCC by the examination of PTEN
protein expression and Akt activation (Akt phosphorylation at
Ser473), a direct down-stream event of PTEN function. In
comparison with adjacent non-tumor kidney tissues, we have
found the co-existence of both high levels of PTEN protein
and increased Akt activation in 17.1% (6/35) of ccRCC
(Table 2). This suggests that PTEN function in these ccRCCs
may be compromised via mechanisms that do not lead to
reduction in PTEN protein.
2. Materials and methods
2.1. Collection of primary RCCs
44 pairs of RCC and their respective non-tumor kidney tissues were collected
in compliance with the local ethics regulations at St. Joseph’s Healthcare
Hamilton, Ontario, Canada. The pathological diagnoses were performed by the
specialists of the hospital. All ccRCCs, pRCCs and their non-tumor kidney
tissues were confirmed by H&E staining. Excluding one pRCC (see Fig. 1A) that
contains both normal and pRCC tissue, all remaining ccRCCs and pRCCs do notcontain any normal kidney tissue. Blood vessels were detected in our RCC
samples. Examination of our RCC tissues showed no detectable macrophage or
lymphocyte infiltration (data not shown).
2.2. Immunohistochemistry
Clear cell RCCs, pRCCs, and matched non-tumor kidney tissue were
mounted on the same slide, deparaffinized, and then heat-treated for 20 min
in a 10 mM sodium citrate buffer at pH=6.0 in a food steamer. Primary
antibody was incubated with the sections overnight at 4 °C at a concen-
tration of 1:100 for an anti-PTEN antibody (Santa Cruz, A2B1, a
monoclonal antibody raised against amino acids 388–400 of human
PTEN) or 1:200 for anti-Ser473 phosphorylated Akt (Cell Signaling).
Biotinylated goat anti-rabbit IgG and ExtrAvidin conjugated peroxidase
(Sigma) were then sequentially added. Chromogen reaction was carried out
with diaminobenzidine, and counterstaing was done with hematoxylin. To
reduce signal variations among individual immunohistochemistry procedures
performed at different times, chromogen reaction was done using the same
stock solutions. We have noticed that different slides from the same block
stained with the same antibody at different times displayed comparable levels
of signal intensity.
2.3. Grading scheme
The intensity of staining was graded on a scale of 0–3+, where 0=no
staining, 1+=very faint staining or staining in a minority of cells, 2+=consistent
staining or staining in the majority of cells, and 3+=staining of the entire
cytoplasm in most cells with high intensity. Sections were blindly scored by
three individuals.
2.4. Tissue lysate preparation and western blot
Frozen renal cancer tissue and corresponding normal renal tissue were
crushed under liquid nitrogen and resuspended in lysis buffer, containing 20 mM
Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
25 mM sodium pyrophosphate, 1 mM NaF, 1 mM β-glycerophosphate, 0.1 mM
sodium orthovanadate, 1 mM PMSF, 2 μg/ml leupeptin and 10 μg/ml aprotinin.
Cell lysate was prepared and western blot was performed according to our
published procedure [20].
2.5. Quantification of PTEN expression and Akt activation
PTEN expression and Akt activation (phosphorylation of Ser 473) in
RCCs and their respective non-tumor kidney tissues were determined by
western blot. Actin levels in these tissues were also examined by western
blot. PTEN levels in RCC and the matched non-tumor kidney tissue were
normalized against their respective actin levels using a densitometry
software program (Scion Imaging for Windows). The normalized PTEN
levels in RCCs were then compared to the normalized PTEN expressions in
the respective non-tumor kidney tissues to derive changes (in fold, RCC/
normal kidney tissue) in PTEN expression in RCC. Following the same
methodology, changes in Akt phosphorylation in RCC compared to the
matched non-tumor kidney tissues were also determined. The results were
summarized in Table 1.
3. Results
3.1. Expression of PTEN and Akt activation in non-tumor
kidney tissues
To investigate PTEN expression in RCC, we collected 44 pairs
ofRCCs, consisting of 35 ccRCCs, and 9 pRCCs, and theirmatched
non-tumor kidney tissues (Table 1). Immunohistochemistry (IHC)
staining revealed that PTENwas expressed predominantly in the
proximal tubules (Fig. 1A middle panel, Fig. 1B, C) with very
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glomeruli (data not shown), which is consistent with a previous
publication [17]. The anti-PTEN antibody specifically detected
PTEN as (1) a control IgG did not produce any detectable signals
(data not shown), (2) in slides mounted with RCC and the
matched non-tumor kidney tissue side by side, a substantial
reduction or negative in PTEN staining in ccRCCwas frequently
observed and (3) in DU145 prostate cancer cells in which PTEN
was knocked-down using siRNA, the antibody detected a
substantial reduction in PTEN by both western blot and
immunofluorescent staining (data not shown). There was some
variation in the levels of PTEN staining from case to case. It is
unlikely that this resulted from variations associated with the
IHC procedure, as variation was seen for slides stained simul-
taneously. Furthermore, in a given patient the levels of PTEN
staining were consistent throughout the entire section as well as
in replicate experiments. Western blot analysis confirmed these
variations in non-tumor tissues (Fig. 2A, comparing the PTEN
expression in the non-tumor tissues among patients 37–40). It is
likely that these variations may be associated with each patient’s
individual clinical characteristics, such as age, previous
medication, or the presence of other kidney complications.
Akt activation requires phosphorylation of Thr308 in the
kinase domain and phosphorylation of Ser473 in the C-terminus
[21]. Phosphorylation of Ser473 is widely used as a marker of
Akt activation [20]. Akt Ser473 phosphorylation was observed
predominantly in the proximal tubules, and not in the
interstitium. There was occasional faint staining of the glomeruli
(Fig. 1A, middle panel). Levels of Akt activation also varied
among individual non-tumor kidney tissues, detected by IHC
staining (data not shown) and western blot (Fig. 2A, see Akt
phosphorylation in the non-tumor tissues of patients 39, 40).
3.2. Reduction in PTEN expression in RCC is associated with
Akt activation
To investigate the relationship between PTEN expression and
Akt activation in RCC, we examined the levels of PTEN protein
and Akt activation in the same pair of tumor and matched non-
tumor tissues by IHC staining and by western blot. PTEN
expression and Akt activation in RCC and their respective non-
tumor tissues were quantified (see Quantification of PTEN
expression and Akt activation for details). Since the cellular
content or cellularity differs in RCC and in non-tumor kidney
tissue, we have normalized PTEN expression and Akt activation
against actin, an intracellular protein. PTEN was reported to be
expressed at reduced levels in 12.5%–55% of ccRCCs, when
compared to the adjacent non-tumor tissues [17]. Indeed, weFig. 1. Expression of PTEN and Akt activation in RCC. (A) pRCC and the matche
staining for PTEN and for Ser473 phosphorylated Akt (Akt p-Ser473) (activated Akt)
tumor tissue (solid arrow, top panel, HE stain). The kidney tubules in the non-tumor t
portion of non-tumor (middle panel) and tumor tissue (bottom panel) are also shown.
tissue were cut and mounted on the same slide, followed by H&E staining and immuno
tissue and PTEN-positive ccRCC are shown. Scale bars represent 50 μm. (C) Non-tum
slide, followed by H&E staining and immunohistochemistry detection of PTEN and
ccRCC (bottom panel) are shown. Scale bars represent 100 μm.observed reduction in PTEN expression in ccRCC by IHC
staining (Fig. 1C) and by western blot (Fig. 2A, comparing the
PTEN protein levels in non-tumor and ccRCC tissues in patients
40 and 66; Fig. 3). 45.7% of ccRCCs (16/35) express reduced
PTEN (Fig. 2B, top panel; Table 2; see Discussion for details). In
9 pRCCs examined, 8 of them express PTEN at reduced levels
(Table 1).
Since PTEN reduces Akt activation, we determined whether
reduction in the PTEN protein is associated with increases in Akt
activation. A large proportion of ccRCCs displayed enhanced
Akt activation (Fig. 2A and B, bottom panel), which consists of
28.6% of ccRCC (Table 2, see the “Total row” with “High”
levels of Akt activation). As expected, when compared to the
matched non-tumor kidney tissues, reduction in PTEN is
associated with increased phosphorylation of Akt Ser473 in
ccRCC, indicative of Akt activation (Fig. 2A, see patients 61, 66;
Fig. 3), and 25.0% (4/16) of ccRCCs that express low levels of
PTEN exhibit increased Akt activation (Table 2). Among 8
pRCCs with reduced PTEN expression, 2 pRCCs show
increased Akt activation (Table 1). Collectively, the above
observations support the notion that attenuation of PTEN
function contributes to Akt activation in RCC.
3.3. Co-existence of RCC expressing high levels of PTEN and
Akt activation
We have demonstrated that 31.6% (6/19) of ccRCCs express
enhanced Akt activation in the presence of high levels of PTEN
expression (Table 2). To further examine the co-existence of
high levels of the PTEN protein with enhanced Akt activation,
we determined whether increased Akt activation exists in the
same tumor sections that express PTEN normally. Matched
ccRCC and non-tumor kidney tissues were serially cut onto
individual slides (each slide contained both tumor and non-
tumor tissues), which were subsequently stained by IHC with
anti-PTEN and anti-Ser473 phosphorylated Akt antibody. We
were able to locate the same ccRCC (Fig. 1B) that express high
levels of PTEN protein and Akt activation. Collectively, these
data support that a subset of ccRCCs contain high levels of
PTEN protein and enhanced Akt activation.
4. Discussion
Previous studies have documented PTEN reduction in a
proportion of ccRCC, relative to PTEN expression in the
normal renal tubules [17]. This contributes to the enhanced
Akt activation observed in a proportion of renal carcinomas
[22] and correlates with adverse clinicopathological featuresd non-tumor tissue was subjected to H&E staining and immunohistochemistry
. The tissue contains both non-tumor tissue (open arrow, top panel, HE stain) and
issue are clearly visible (top panel, HE stain). Higher magnification images for a
Scale bars represent 100 μm. (B) Non-tumor tissue and clear cell RCC (ccRCC)
histochemistry detection of PTEN and activated Akt (Akt p-Ser473). Non-tumor
or tissue and clear cell RCC (ccRCC) tissue were cut and mounted on the same
activated Akt (Akt p-Ser473). Non-tumor tissue (top panel) and PTEN-negative
Table 1
PTEN expression and Akt activation (Akt p-Ser473) in ccRCC and pRCC
Patients a Fuhrman's nuclear
grade/tumor size (cm) b
Akt p-Ser473
ratio (RCC/normal) c
PTEN ratio
(RCC/normal) c
Akt activation d
PTEN L e PTEN N e PTEN H e
03 ccRCC 3/5.5 cm 0.27 1.90 L d
05 ccRCC 4/8 cm 0.24 0.60 L d
06 ccRCC 2/3.5 cm 0.28 1.59 L
07 ccRCC 3/11 cm 0.69 1.40 L
08 ccRCC 4/ 1.07 0.93 Nd
09 ccRCC 3/15 cm 0.58 0.37 L
14 ccRCC 1/3.6 cm 0.13 0.69 L
20 ccRCC 3/5.5 cm 1.01 1.23 N
22 ccRCC 3/11 cm 0.03 0.45 L
23 ccRCC 2/2.9 cm 2.02 1.51 H
26 ccRCC 2/6.5 cm 0.29 5.75 L
27 ccRCC 2/5.5 cm 4.14 0.94 H
29 ccRCC 3/4.5 cm 0.61 1.05 L
30 ccRCC 1/4.0 cm 0.56 1.59 L
31 ccRCC 3/7.0 cm 2.16 1.42 H
34 ccRCC 2/4.5 cm 0.66 1.01 L
35 ccRCC 3/7.4 cm 1.26 0.24 N
37 ccRCC 1/1.0 cm 0.99 2.59 N
38 ccRCC 3/3.5 cm 0.98 0.86 N
40 ccRCC 2/11.5 cm 2.69 0.22 H
41 ccRCC 2/4.0 cm 0.72 0.96 L
42 ccRCC 2/NA 0.41 0.09 L
45 ccRCC 2/2.0 cm 0.9 0.32 N
46 ccRCC 2/5.0 cm 0.9 0.81 N
48 ccRCC 2/5.4 cm 3.77 0.16 H
52 ccRCC 2/1.2 cm 0.37 1.12 L
54 ccRCC 2/2.9 cm 1.60 1.16 H
56 ccRCC 2/5.5 cm 2.07 0.99 H
57 ccRCC 4/7.0 cm 1.22 0.21 N
59 ccRCC 1/NA 0.51 0.85 L
61 ccRCC 3/NA 4.15 0.82 H
62 ccRCC 2/5.2 cm 0.84 0.71 L
65 ccRCC 1/4.0 cm 2.25 0.96 H
66 ccRCC 1/4.5 cm 3.42 0.46 H
67 ccRCC 1/6.2 cm 0.56 0.93 L
11 pRCC 2/1.8 cm 0.06 0.36 L
19 pRCC 3/6.0 cm 1.45 0.23 N
21 pRCC 3/4.0 cm 0.23 2.17 L
28 pRCC 1/3.5 cm 4.55 0.11 H
36 pRCC 3/3.5 cm 0.18 0.33 L
39 pRCC 2/7.5 cm 1.37 0.67 N
47 pRCC 3/30. cm 0.22 0.39 L
50 pRCC 3/3.0 cm 1.18 0.26 N
55 pRCC 2/2.8 cm 3.07 0.47 H
a Patient number and tumor type.
b Tumor grades and sizes in maximal diameters, NA: not available.
c Akt activation (Akt p-Ser473) and PTEN expression in a given sample were normalized against actin. The ratios of Akt activation (Akt p-Ser473) or
PTEN expression in RCC are compared to those in matched non-tumor tissues (see Materials and Methods for details).
d Akt activation is defined as L (low), N (normal), and H (high) if the ratios are less than 90%, between 90% and 149%, higher than 150%, respectively.
e PTEN expression levels in ccRCC are defined as L (low), N (normal), and H (high) if the ratios are less than 90%, between 90% and 149%, higher than 150%,
respectively.
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concept that RCC inactivates PTEN by reducing its expres-
sion. Numerous experiments demonstrate that PTEN dom-
inantly inhibits Akt activation. While homozygous deletion of
PTEN is embryonic lethal in Drosophilia, flies with knockout
of PTEN and concomitant reduction of Akt activation (via a
mutation in its pleckstrin homology (PH) domain to reduce the
affinity of its PH domain for PIP3) develop normally withelevated levels of PI(3, 4, 5)P3 [23,24]. PTEN+/− mice
develop tumors in the gastrointestinal tract, prostate, breast,
adrenal, thyroid, and endometrial tissue with enhanced Akt
activation [25–29], which is largely prevented by co-knockout
of Akt1 [15]. Therefore, the existence of putative PTEN-
negative regulators has recently been proposed in human
cancer based on the observation that only a small proportion
of breast cancers have PTEN mutations and a much larger
Fig. 2. Western blot analysis of PTEN expression and Akt activation in RCC and matched non-tumor tissues. (A) Tissue lysate was prepared as described in Materials
and methods. The expression of PTEN, Akt, Akt activation, and actin in RCC (C) and the adjacent non-tumor kidney tissues (N) was examined by western blot using
specific antibodies. All samples are ccRCCs, excluding patient 39 (pRCC). (B) PTEN expression and Akt activation were normalized against actin. The levels of
PTEN expression and Akt activation relative to those in the matched non-tumor tissues (Cancer/Normal) were determined and their distribution was graphed. The
horizontal line shows an equal expression of PTEN and Akt activation between ccRCC and the matched non-tumor kidney tissue. Data points above or below the line
represent ccRCCs that express increased or decreased PTEN and Akt phosphorylation, respectively.
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[30].
Our study in ccRCC supports this concept. While 25.0% of
ccRCCs that express PTEN at reduced levels relative to the
matched non-tumor tissues showed increased Akt activation,
31.6% of ccRCCs with comparable or higher levels of PTEN
also have increased Akt activation (Table 2). The fact that PTEN
expression is higher in some ccRCCs than in their respectivenon-tumor tissues suggests attenuation of PTEN function. In
this study, we defined PTEN expression as low if ccRCCs
express less than 90% of PTEN compared to the matched non-
tumor kidney tissue (Table 1). While this may over-estimate
ccRCC-associated PTEN reduction, it establishes a more
stringent condition for the examining the co-existence of high
levels of PTEN expression and enhanced Akt activation. A
similar study investigating the relationship between PTEN
Fig. 3. The expression of PTEN and P-Akt in ccRCC. PTEN expression and Akt activation were normalized against actin. The levels of the PTEN protein and Akt
activation in ccRCCs were expressed as ratios relative to the levels of PTEN and Akt activation in the matched non-tumor tissues. ⁎: ccRCCs with increased Akt
activation in the presence of normal or high levels of PTEN; #: ccRCCs with enhanced Akt activation in the presence of reduced PTEN expression. Data were
summarized in Table 1.
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an inverse correlation between PTEN expression and Akt
phosphorylation was seen in ccRCC [31]. While we indeed
observed an increase in Akt activation with reduction of PTEN
expression in ccRCC, we have also demonstrated enhanced Akt
activation in the presence of high levels of PTEN expression. To
our knowledge, this is the first demonstration of the co-
existence of high levels of PTEN protein with enhanced Akt
activation in ccRCC.
Our observation that only 25.0% of ccRCCs with reduction
in PTEN expression display increased Akt activation indicates
that either a threshold of PTEN reduction is required for Akt
activation or additional factors downstream of PI3K-PTEN may
also play a role in Akt activation in ccRCC. In this investigation,Table 2
Expression of PTEN and Akt activation (Akt p-Ser473) in clear cell renal cell
carcinoma
PTENa n b % Akt activation (Akt p-Ser473) c
Low Normal High
Low 16 45.7 7/16 (43.7%) d 5/16 (31.3%) d 4/16 (25.0%) d
Normal 13 37.1 6/13 (46.1%) d 2/13 (15.4%) d 5/13 (38.5%) d
High 6 17.1 4/6 (66.7%) d 1/6 (16.6%) d 1/6 (16.6%) d
Total 35 100 17/35 (48.6%) d 8/35 (22.8%) d 10/35 (28.6%) d
Normal/High 19 54.3 10/19 (52.6%) d 3/19 (15.8%) d 6/19 (31.6%) d
a Low, normal, and high levels of PTEN expression in ccRCC are defined in
Table 1.
b Number of patients.
c Akt activation is determined by phosphorylation on Ser473 (Akt p-Ser473)
and the low, normal, and high levels of Akt activation in ccRCC are defined in
Table 1.
d Percentage of Akt activation in the individual PTEN expression groups and
in the total ccRCC population, respectively. Data are derived from Table 1.we show 28.6% (10/35) (Table 2) of ccRCCs have elevated Akt
activation, indicative of attenuation in PTEN function. Among
this population, 40% (4/10) (Table 2) express reduced PTEN,
while 60.0% (6/10) (Table 2) contain either normal or increased
levels of the PTEN protein. Thus, our results suggest not only
the existence of novel mechanisms leading to attenuation of
PTEN function without reducing PTEN expression, but also
that these mechanisms are a major contributor (in comparison to
reduction of the PTEN protein) to the attenuation of PTEN
function in ccRCC. While Akt activation also requires factors,
such as PDK1 and mTOR [32], PIP3 is the most upstream factor
which dictates Akt activation and is directly regulated by PI3K
and PTEN. Therefore, to activate Akt in the presence of normal
or elevated PTEN protein, mechanisms have to be in place to
reduce PTEN action. These mechanisms may either directly
attenuate PTEN function without reduction in the PTEN protein
or enhance PI3K activation.
While loss of PTEN due to genetic and/or epigenetic events
has been thoroughly investigated, the mechanisms that attenuate
PTEN function without reduction of PTEN protein expression
remain largely elusive. The latter mechanisms may include (1)
actions that reduce PTEN membrane recruitment, (2) post-
translational modifications, (3) putative PTEN-negative reg-
ulators, and 4) PTEN mutations. The site of action for PTEN is
located on the plasma membrane, where it can dephosphorylate
membrane bound PIP3. However, PTEN normally resides away
from the plasma membrane [33,34]. Two N-terminal cationic
clusters (residues R11/K13/R14/R15 and R161/K163/K164)
are essential in mediating the interaction of PTEN with the
anionic lipid plasma membrane [35]. A point mutation of K13
to glutamic acid (E) (K13E) was identified in a human glioma
[36]. The resulting PTEN/K13E mutant is defective in cell
1141L. He et al. / Biochimica et Biophysica Acta 1772 (2007) 1134–1142membrane recruitment [37]. Phosphorylation of three C-
terminal residues, S380, T382 and T383, substantially reduces
PTEN membrane recruitment via neutralization of the positive
charges present in R161/K163/K164 [35]. The C2 domain of
PTEN also plays a critical role in its membrane recruitment
[38]. Reactive oxygen species have been shown to oxidize the
catalytic cysteine residue (C124), resulting in inactivation of
PTEN phosphatase activity [39]. Since the identification of DJ-
1 as a putative PTEN-negative regulator [40], the existence of
PTEN-negative regulators has been suggested [30]. In addition,
mutations leading to changes in critical amino acid residues may
also inactivate PTEN despite the detection of normal levels of
PTEN protein expression. An example is a Cowden disease-
derived mutation (G129E) that specifically inactivates PTEN’s
PIP3 phosphatase activity [9,38].
Thus, the potential mechanisms that compromise PTEN
function in RCC without reduction of PTEN protein may
include all the aforementioned mechanisms. However, it should
be emphasized that except for mutations in the PTEN gene
which have been well documented in human cancers, the
existence of other aforementioned mechanisms in human cancer
has yet to be convincingly demonstrated. Mutation in the PTEN
gene in ccRCC has been well documented to be a rare event
[16,19,41]. Since we have observed 17.1% (6/35) ccRCCs that
display high levels of PTEN with increased Akt activation, our
observations support the concept that in ccRCC, PTEN function
is compromised by the mechanisms that either prevent PTEN
from functioning properly (see the above discussion for details)
or enhance PI3K function.
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